Advanced Malignancies Clinical Trial
Official title:
A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies
The primary objective of this study is to allow rollover of the two remaining subjects from
the other XL999 studies to continue to receive XL999.
The secondary objectives of this study are as follows:
- To evaluate tumor response after long term repeat administration of XL999 in two
subjects rolled over from other XL999 studies.
- To characterize the long term safety and tolerability of XL999 after repeat
administration in two subjects rolled over from other XL999 studies.
- To characterize the long term effects of XL999 on cardiac function after repeat
administration in two subjects rolled over from other XL999 studies.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Completed |
NCT00948961 -
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Terminated |
NCT02265510 -
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03907969 -
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
|
Phase 1/Phase 2 | |
| Completed |
NCT03241173 -
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT02923349 -
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04025957 -
A Study of SHR-1501 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT05048134 -
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00651664 -
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06038058 -
A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00611793 -
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
| Not yet recruiting |
NCT05987605 -
Clinical Study of 1A46 Drug Substance
|
Phase 1 | |
| Terminated |
NCT02608268 -
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT03277352 -
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05577182 -
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT04831996 -
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
|
Phase 1 | |
| Recruiting |
NCT06468098 -
A Study of IBI363 in Subjects With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT02737501 -
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
|
Phase 3 |